Revenue Expected to Grow by 9-11%
- CONMED Corporation announces preliminary financial information for Q3 2024
- Revenue expected between $315M and $318M
- Adjusted diluted net earnings per share growth of 9% to 11%
- Full results to be reported on October 30, 2024
- Conference call at 4:30 p.m. ET on October 30, 2024
CONMED Corporation has announced preliminary financial information for the third quarter of 2024, with revenue expected to be between $315 million and $318 million. The company also expects an adjusted diluted net earnings per share growth in excess of its previously provided guidance of 9% to 11%. Full financial results will be reported after the market close on October 30, 2024. A conference call will take place at 4:30 p.m. ET that day to discuss the results. The information is preliminary and subject to completion; actual results may differ.
Factuality Level: 9
Factuality Justification: The article provides accurate and relevant information about CONMED Corporation’s preliminary financial results for the third quarter of 2024. It includes a clear disclaimer that the information is preliminary and subject to change after the completion of financial closing procedures. The article also mentions forward-looking statements with appropriate caution and references to risk factors, which demonstrates a high level of factuality.
Noise Level: 7
Noise Justification: The article provides preliminary financial information for a company’s third quarter performance and includes forward-looking statements. While it may be relevant for investors following the company’s stock performance, it lacks in-depth analysis or context that would make it more informative for a broader audience.
Public Companies: CONMED Corporation (CNMD)
Key People:
Financial Relevance: Yes
Financial Markets Impacted: No
Financial Rating Justification: The article discusses preliminary financial information for the third quarter of 2024 from CONMED Corporation, a medical technology company. It mentions revenue and adjusted diluted net earnings per share growth expectations. However, it does not directly impact any specific financial markets or companies.
Presence Of Extreme Event: No
Nature Of Extreme Event: Other
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: The article discusses the financial performance of a medical technology company and does not mention any extreme event. There is no extreme event in the text.
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Up
Magnitude: Medium
Affected Instruments: Stocks
www.businesswire.com 
